

Can the drug delivery systems match the pace?

13 September 2011 | News



The market for biological drugs, which is already well over \$100 billion, continues to grow at a fast clip, besides getting more complex in nature. Taking these biologic drugs to market and insuring their quick adoption mighty depends on the delivery systems available. Precision delivery methodologies are required. The question is: can the drug delivery systems match the parce tand/deliver ti??* the unknown. Nandita Singh The author is Editor of BioSpectrum and the drugs are somewhat getting fused together. This brings forth exciting possibilities. We already have been hearing about needle-free novel delivery mechanisms such as patches and editive vastems available. These and editive vastems available vascines. There are many transpaticle uses calcium phosphate as a cap to contain the drug, which disolves only when it comes in contact with the high levels of acidity in cancer cells. Dr Leve Sang-cheon of Kyunghee University led his research group. In another development, a research team at MIT, led by Dr Ali Khadernhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koh Institute professor, the two of opportunity. Challenges also abound. Science is always a challenge, However, that's not the only challenge. Here solved have been hearing is not not white might exceed of opportunity. Challenges also abound. Science is always a challenge, However, that's not the only challenge. After science, the next dig challenge that the companies need to contained with is synergizing these developments at the drug delivery used and the drug window of opportunity. Challenges also a conversation on this page of BioSpectrum. I look forward to hearing form you.	Nanditasingh progress in biomedicine is d	Drug delivery innovations will be critical in driving the biomedicine industry. In fact, further ependent on the advances in the drug delivery systems.
Nandita Singh The author is Editor of BioSpectrum nandtas@cybarmedia.co.in randtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtas@cybarmedia.co.in andtable vaccines. There are many companies more-defined time lag release for high efficacy. Drug delivery and the drugs are somewhat getting fused together. This brings forth exciting possibilities. We already have been hearing about needle-free novel delivery mechanisms such as patches and edible vaccines. There are many high potential developments in the offing. In August, this and edible vaccines. There are many high potential developments in the offing. In August, this and edible vaccines. There are many high potential developments in the offing. In August, this and edible vaccines. There are many high potential developments in the offing. In August, this and edible vaccines. There are many companies and rescan contact with the high levels of acidity in cancer cells. Dr Lee Sang-cheon of Kyunghee University led this research group. In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology. and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a temperature-sensitive material that shrinks when heated. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also abound. Science is always a challenge. However, that's not the only challenge. After science, the ex- thy delivery technology companies and research insti		The market for biological drugs, which is already well over \$100 billion, continues to grow at a fast clip, besides getting more complex in nature. Taking these biologic drugs to market and ensuring their quick adoption majorly depends on the delivery systems available. Precision delivery methodologies are required. The question is: can the drug delivery systems match the
The author is Editor of BioSpectrum nandias@cybarnedia.coin fancyarticles, microencapsulation, and polymer technology are driving their initiatives. These advances in manoparticles, microencapsulation, and polymer technology are driving their initiatives. These advances are evolving the drug delivery system itself to work closely with the therapeutic being delivered in a targeted manner with pre-delined time lag release for high efficacy. Drug delivery and the drugs are somewhat getting fused together. This brings forth exciting possibilities. We already have been hearing about needle-free novel delivery mechanisms such as patches and edible vaccines. There are many high potential developments in the offing. In August, this year, South Korean scientists announced that they have developed a nanoparticle anti-cancer drug delivery system. This nanoparticle uses calcium phosphate as a cap to contain the drug, which dissolves only when it comes in contact with the high levels of acidity in cancer cells. Dr Lee Sang-cheon of Kyunghee University led this research group. In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a temperature-sensitive material that shrinks when heated. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also abound. Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesti	pace and deliver it?or type un	nown
and the drugs are somewhat getting fused together. This brings forth exciting possibilities. We already have been hearing about needle-free novel delivery mechanisms such as patches and edible vaccines. There are many high potential developments in the offing. In August, this year, South Korean scientists announced that they have developed a nanoparticle anti-cancer drug delivery system. This nanoparticle uses calcium phosphate as a cap to contain the drug, which dissolves only when it comes in contact with the high levels of acidity in cancer cells. Dr Lee Sang-cheon of Kyunghee University led this research group. In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a temperature-sensitive material that shrinks when heated. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also abound. Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesting to hear stories of such collaborations, challenges met and the consequent gins. So, 1 am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	I he author is Editor of BioSpectrum nanditas@cybermedia.co.in	There are many companies working in the area. Applications of technological advances in nanoparticles, microencapsulation, and polymer technology are driving their initiatives. These advances are evolving the drug delivery system itself to work closely with the therapeutic being delivered in a targeted manner with pre-defined time lag release for high efficacy. Drug delivery
We already have been hearing about needle-free novel delivery mechanisms such as patches and edible vaccines. There are many high potential developments in the offing. In August, this year, South Korean scientists announced that they have developed a nanoparticle anti-cancer drug delivery system. This nanoparticle uses calcium phosphate as a cap to contain the drug, which dissolves only when it comes in contact with the high levels of acidity in cancer cells. Dr Lee Sang-cheon of Kyunghee University led this research group. In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a temperature-sensitive material that shrinks when heated. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also abound. Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	and the drugs are somewha	t getting fused together. This brings forth exciting possibilities.
In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a lemperature-sensitive material that shrinks when heated. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also abound. Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	Lee Sang-cheon of Kyungh	We already have been hearing about needle-free novel delivery mechanisms such as patches and edible vaccines. There are many high potential developments in the offing. In August, this year, South Korean scientists announced that they have developed a nanoparticle anti-cancer drug delivery system. This nanoparticle uses calcium phosphate as a cap to contain the drug, which dissolves only when it comes in contact with the high levels of acidity in cancer cells. Dr ee University led this research group.
abound. By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	temperature-sensitive mater	In another development, a research team at MIT, led by Dr Ali Khademhosseini, associate professor in the MIT-Harvard Division of Health Sciences and Technology, and Robert Langer, the David H. Koch Institute professor, met the same challenge by building micromolds out of a jial that shrinks when heated.
Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for successful outcomes at various levels. It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	abound.	By some rough estimates, the drug delivery systems market will most likely cross \$10 billion, globally, by the end of this decade. And that is a huge window of opportunity. Challenges also
It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.	successful outcomes at vari	Science is always a challenge. However, that's not the only challenge. After science, the next big challenge that the companies need to contend with is synergizing these developments at the drug delivery technology companies and research institutes with the companies that need these technologies. And therein lies the next level of challenge in finding ways to collaborate for ous levels.
		It would be interesting to hear stories of such collaborations, challenges met and the consequent gains. So, I am opening a conversation on this page of BioSpectrum. I look forward to hearing from you.